Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company previously planned to offer 7.8 million shares. At $17, Lucira commands a fully diluted market cap of $705 million.
Lucira Health plans to list on the Nasdaq under the symbol LHDX. BofA Securities, William Blair and LifeSci Capital acted as lead managers on the deal.
